Model Prospera - Kidney Transplant Assessment
From Organ Health Test
Covered by Medicare, Prospera is a transplant rejection assessment test that uses a simple blood draw to evaluate the risk of rejection of a transplanted kidney. Through the use of advanced cell-free DNA technology, Prospera increases a provider’s ability to identify otherwise undetected rejection that might lead to kidney loss. Catching transplant rejection as soon as possible can help providers develop a treatment plan to best protect the donated kidney.
-
Most popular related searches
Overview
Prospera offers more precise post-transplant rejection assessment
With a 95% negative predictive value, Prospera misses ~3x fewer rejections than serum creatinine.1 Prospera’s proprietary donor-derived cell-free DNA (dd-cfDNA) technology offers early warning signs of transplant rejection and reduces the likelihood of renal allograft failure with a non-invasive single blood draw.1,2
Why now?
Organ rejection is a problem
Many kidney transplant failures occur within the first five to ten years7,8 because organ rejection isn’t caught early enough or treated effectively. As a result, the patient needs a new organ and must start the waitlist process again.
Why choose Prospera for rejection assessment?
Built on our deep experience and legacy in cell-free DNA, Prospera is:
- Covered by Medicare
- Medicare logo
- More simple and less invasive than biopsy
- More accurate than current assessment tools across all types of rejection1
- Up to 5x less variable than first-generation donor-derived cell-free DNA technology1,3
- Uniquely quantifies absolute dd-cfDNA and total cfDNA along with donor fraction for improved sensitivity9
Patient Information
Surveilling your new kidney with a more precise blood draw
More informed, better protection
You and your provider understand the importance of preserving the function of a newly transplanted kidney. Achieving this goal could mean avoiding both dialysis and returning to the transplant list.
Early, informed treatment of underlying disease and patient adherence to medications are essential to preserving kidney function.
How does it work?
From a single blood draw, Prospera measures the amount of donor DNA from your transplanted kidney in your blood. This helps your care team assess all types of rejection more precisely than available standard assessment tools.1-4
What do the Prospera results mean to me?
The Prospera result represents the percent of cell-free DNA in your blood that originates from the donated kidney to determine whether or not you may be experiencing active rejection. It may also indicate other types of kidney injury you are experiencing.
Like your other regular monitoring tests, Prospera is recommended for periodic use over time as directed by your doctor.
A WAY TO TRACK YOUR CELL-FREE DNA OVER TIME
- Establishing a baseline tells you and your care team the “normal state” of your new kidney. You can measure new results against this baseline.
- Following your levels in the future reveals your new kidney’s health
IF A PROSPERA RESULT IS ABOVE 1%
This may mean that active rejection is occurring2. Terms used to describe the various types of active rejection include:
- Antibody-mediated rejection
- T cell-mediated rejection
- Mixed rejection
To confirm a rejection or the type of rejection, you should consult your doctor.
IF A PROSPERA RESULT IS IN THE NORMAL RANGE
- This may mean that your kidney is stable2.
ProsperaLink Program: Your Support Team
We offer complete support through our Prospera Link Program:
Always by your side: Natera’s care team will guide you through the process of using Prospera and check-in with you at every milestone
Flexible for your convenience: Our team coordinates blood draws around your schedule — at a certified laboratory near you or by a blood draw specialist who can come to you
Transparent & accessible: Our proactive billing outreach and flexible payment plans, including assistance for hardship, help ensure no significant financial hardship in accessing Prospera. Natera welcomes all insurances. Prospera is covered by Medical for assessing potential kidney transplant rejection.
Clinician Information
Want more precise post-transplant assessments?
A comprehensive view of your patient’s rejection status: providers could improve their post-transplant rejection assessments by more than 50%.6 In a recently published clinical validation study, donor-derived cell-free DNA was more reliable than serum creatinine in identifying all types of rejection.1
What is the Prospera test?
PROS_download-brochure
Prospera is a transplant rejection test that uses a simple blood draw to assess the risk of rejection of a transplanted kidney.
Through the use of advanced cell-free DNA technology, Prospera increases a provider’s ability to identify otherwise undetected rejection that might lead to kidney loss. Catching transplant rejection as soon as possible can help providers develop a treatment plan to best protect the donated kidney.
What makes Prospera different?
Built on our deep experience and legacy in cell-free DNA, Prospera is:
- Highly optimized to significantly reduce variability
- Medicare logo
- Now - catch ALL rejection types with a single blood draw
- Lower risk of missing active rejection
- Ultra-sensitive for more accurate classification
- Unparalleled precision
- Now quantify the risk - run a cfDNA background check every time
Refined Workflow. Only from Natera
Natera has performed over three million cell-free DNA (cfDNA) tests across women’s health and oncology. Harnessing this expertise, only Prospera uses one-of-a-kind, third-generation cfDNA technology to differentiate between self cfDNA and cfDNA from another source—such as a donated organ.
Customer reviews
No reviews were found for Model Prospera - Kidney Transplant Assessment. Be the first to review!